EUR 116.6
(0.17%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 1.92 Billion EUR | 4.43% |
2022 | 1.83 Billion EUR | -43.73% |
2021 | 3.26 Billion EUR | 15.58% |
2020 | 2.82 Billion EUR | 2.74% |
2019 | 2.75 Billion EUR | 10.8% |
2018 | 2.48 Billion EUR | 7.45% |
2017 | 2.31 Billion EUR | 3.98% |
2016 | 2.22 Billion EUR | -1.61% |
2015 | 2.25 Billion EUR | 23.09% |
2014 | 1.83 Billion EUR | 1.7% |
2013 | 1.8 Billion EUR | 1.05% |
2012 | 1.78 Billion EUR | -4.42% |
2011 | 1.86 Billion EUR | 4.69% |
2010 | 1.78 Billion EUR | 3.55% |
2009 | 1.72 Billion EUR | 8.73% |
2008 | 1.58 Billion EUR | -5.36% |
2007 | 1.67 Billion EUR | 4.99% |
2006 | 1.59 Billion EUR | 56.57% |
2005 | 1.01 Billion EUR | 42.46% |
2004 | 715.25 Million EUR | -9.58% |
2003 | 791.02 Million EUR | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 1.92 Billion EUR | 0.0% |
2023 FY | 1.92 Billion EUR | 4.43% |
2023 Q2 | 1.89 Billion EUR | 0.0% |
2023 Q4 | 1.92 Billion EUR | 0.0% |
2022 Q2 | 3.52 Billion EUR | 0.0% |
2022 FY | 1.83 Billion EUR | -43.73% |
2022 Q4 | 1.83 Billion EUR | 0.0% |
2021 FY | 3.26 Billion EUR | 15.58% |
2021 Q4 | 3.26 Billion EUR | 0.0% |
2021 Q2 | 2.99 Billion EUR | 0.0% |
2020 FY | 2.82 Billion EUR | 2.74% |
2020 Q4 | 2.82 Billion EUR | 0.0% |
2020 Q2 | 2.76 Billion EUR | 0.0% |
2019 Q2 | 2.55 Billion EUR | 0.0% |
2019 Q4 | 2.75 Billion EUR | 0.0% |
2019 FY | 2.75 Billion EUR | 10.8% |
2018 Q4 | 2.48 Billion EUR | 0.0% |
2018 FY | 2.48 Billion EUR | 7.45% |
2018 Q2 | 2.37 Billion EUR | 0.0% |
2017 Q2 | 2.23 Billion EUR | 0.0% |
2017 FY | 2.31 Billion EUR | 3.98% |
2017 Q4 | 2.31 Billion EUR | 0.0% |
2016 FY | 2.22 Billion EUR | -1.61% |
2016 Q2 | 2.08 Billion EUR | 0.0% |
2016 Q4 | 2.22 Billion EUR | 0.0% |
2015 FY | 2.25 Billion EUR | 23.09% |
2015 Q2 | 1.94 Billion EUR | 0.0% |
2015 Q4 | 2.25 Billion EUR | 0.0% |
2014 Q4 | 1.83 Billion EUR | 0.0% |
2014 Q2 | 1.79 Billion EUR | 0.0% |
2014 FY | 1.83 Billion EUR | 1.7% |
2013 FY | 1.8 Billion EUR | 1.05% |
2013 Q4 | 1.8 Billion EUR | 0.0% |
2013 Q2 | 1.77 Billion EUR | 0.0% |
2012 Q4 | 1.78 Billion EUR | 0.0% |
2012 Q2 | 1.86 Billion EUR | 0.0% |
2012 FY | 1.78 Billion EUR | -4.42% |
2011 Q2 | 1.84 Billion EUR | 0.0% |
2011 FY | 1.86 Billion EUR | 4.69% |
2011 Q4 | 1.86 Billion EUR | 0.0% |
2010 Q2 | 1.82 Billion EUR | 0.0% |
2010 FY | 1.78 Billion EUR | 3.55% |
2010 Q4 | 1.78 Billion EUR | 0.0% |
2009 Q4 | 1.72 Billion EUR | 0.0% |
2009 FY | 1.72 Billion EUR | 8.73% |
2008 FY | 1.58 Billion EUR | -5.36% |
2007 FY | 1.67 Billion EUR | 4.99% |
2006 FY | 1.59 Billion EUR | 56.57% |
2005 FY | 1.01 Billion EUR | 42.46% |
2004 FY | 715.25 Million EUR | -9.58% |
2003 FY | 791.02 Million EUR | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Nicox S.A. | 52.98 Million EUR | -3524.47% |
European Medical Solutions | 43.75 Million EUR | -4288.328% |
FERMENTALG | 50.24 Million EUR | -3721.838% |
argenx SE | 4.11 Billion EUR | 53.303% |
BioSenic S.A. | 9.55 Million EUR | -19988.34% |
Celyad Oncology SA | 16.28 Million EUR | -11693.664% |
Hyloris Pharmaceuticals SA | 47.68 Million EUR | -3927.274% |
Onward Medical N.V. | 43.62 Million EUR | -4301.303% |
Oxurion NV | 6.55 Million EUR | -29216.709% |
PHAXIAM Therapeutics S.A. | 51.3 Million EUR | -3642.656% |
UCB SA | 15.53 Billion EUR | 87.642% |